Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
OBJECTIVE
A phase I dose-escalation study of ifosfamide, carboplatin, and etoposide (ICE) with autologous stem-cell rescue (ASCR) was conducted to determine the maximum-tolerated dose (MTD) of ICE given over 6 days.


METHODS
One hundred fifty-four patients with a variety of poor-prognosis malignancies received escalating doses of ifosfamide 6,000 to 24,000 mg/m2, carboplatin 1,200 to 2,100 mg/m2, and etoposide 1,800 to 3,000 mg/m2 divided over 6 days. Mesna was administered in a dose equal to ifosfamide. ASCR was performed 48 hours after the completion of ICE. The source of stem cells was bone marrow (BM) in patients without BM micrometastases and peripheral-blood stem cells (PBSC) in patients with BM micrometastases. Patients were evaluated for hematologic and nonhematologic toxicities, as well as response to therapy.


RESULTS
The MTD of the ICE regimen is 20,100 mg/m2 of ifosfamide, 1,800 mg/m2 of carboplatin, and 3,000 mg/m2 of etoposide. The dose-limiting toxicities of ICE were CNS toxicity and acute renal failure. Additionally, reversible elevations of serum creatinine levels were noted in 29% of patients treated at the upper dose levels. Forty-six patients were treated at the MTD. Severe, reversible mucositis and enteritis were the major nonhematologic toxicities seen at the MTD (78% and 33%, respectively). The overall mortality rate was 8% for all dose levels (4% at the MTD). At the MTD, the median times to an absolute neutrophil count > or = 0.5 x 10(9)/L, to a platelet count > or = 20 x 10(9)/L, and to discharge were 18, 22, and 24 days, respectively. The overall response rate was 40% for 77 patients with assessable disease at the time of treatment.


CONCLUSIONS
ICE is well tolerated, with acceptable hematopoietic side effects and predictable organ toxicity.
Fields
K K
KK
Department of Internal Medicine, University of South Florida, Tampa 33612.
Elfenbein
G J
GJ
Lazarus
H M
HM
Cooper
B W
BW
Perkins
J B
JB
Creger
R J
RJ
Ballester
O F
OF
Hiemenz
J H
JH
Janssen
W E
WE
Zorsky
P E
PE
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000633:toxicity*; D001943:Breast Neoplasms / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity; D004361:Drug Tolerance; D005047:Etoposide / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D018237:Germinoma / Q000188:drug therapy; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000633:toxicity; D007938:Leukemia / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy; D014182:Transplantation, Autologous
D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide